Intra-Peritoneal Hemostasis Device (IPHD)

  A device for rapid management of non-compressible torso hemorrhage (NCTH) in a variety of environments. This rapidly deployable device will be percutaneously inserted into the abdomen and inflated to stop bleeding at the scene of the injury while en-route to a higher echelon of care.

Value Proposition

There are currently no approved devices for the treatment of NCTH in the pre-hospital setting, where 90% of (potentially survivable) mortality from hemorrhage occurs. This device will prolong survival either during transport to higher echelons of care, or while waiting for definitive surgical care. The IPHD will also maintain patients’ physiologic reserve which may improve overall resuscitative outcomes.

Competitive Advantage

This new hemostasis intervention will address the limitations of current methodologies:

Minimally invasive application and removal
Will not cause the severe and potentially life-threatening complications related to some other interventions
Preserves a casualty’s physiologic reserve and serve as a bridge between the time of initial injury and implementation of definitive treatments (e.g., surgery) once they reach advanced levels of care
Includes design characteristics needed for application in austere or combat environments, and it will be suitable for both military and civilian pre-hospital use

Unique Features

Minimally invasive application and removal

This rapidly deployable device will be percutaneously inserted into the abdomen and inflated to stop bleeding at the scene of the injury, while en route to a higher echelon of care, or while awaiting surgical intervention at higher echelons of care.

These products have established agreements with companies and/or manufacturers.

Licensing Information
Precision Trauma in 2020

Principal Investigators
Kevin Ward, MD
Hakam Tiba, MD, MS

Intellectual Property
Invention Disclosure # 2020-129
Patent Applications Submitted

Solution Sheet
Download Solution Sheet (PDF)

MARKET OPPORTUNITY
While this device can address the same market as current REBOA offerings, it has the advantage of also addressing austere environments like combat casualties and remote geographic locations. The GROA product is similar in applicability but requires occlusion of the aorta The IPHD can be used for inferior aortic occlusion (if the operator chooses to do so) but also works using intra-abdominal pressure and tamponade (similar to ResQFoam).

Contact Precision Trauma for more information about investment and partnership opportunities.